Table 2. Short term outcomes from randomised phase III studies integrating oxaliplatin as radiosensitizer.
Outcomes | STAR-01 (Aschele 2011) (34) |
ACCORD- 0405 (Gerard 2010) (38) |
CAO/ARO/AIO-04 (Rodel 2012) (39) |
NSABP R04 (Roh 2010) (40) |
||||
---|---|---|---|---|---|---|---|---|
5-FU 379 | OXA 352 | Cape 293 | OXA 291 | 5-FU 624 | OXA 613 | 5-FU/cape 622 | OXA 631 | |
ypCR | 16% | 16% | 14% | 19% | 13% | 17% | 19% | 21% |
Ypn+ | 26% | 29% | 30% | 28% | 30% | 28% | Not stated | Not stated |
G3/G4 diarrhoea | 4% | 15% | 3% | 13% | 8% | 12% | 7% | 15% |